Anti-galanin antibodies and uses thereof

Details Anti-galanin antibodies and uses thereof Anti-galanin antibodies and uses thereof

2008-05-13

2008-05-13

Helms, Larry R. (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388220

Reexamination Certificate

active

11009443

ABSTRACT:
The present invention provides antibodies that immunospecifically bind to a galanin peptide and compositions comprising said antibodies. The present invention also provides methods for preventing, treating, managing, and/or ameliorating hyperproliferative disorders or a symptom thereof comprising administering to a subject in need thereof one or more antibodies that immunospecifically bind to a galanin peptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing hyperproliferative disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to a galanin peptide.

REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4631211 (1986-12-01), Houghten
patent: 4676980 (1987-06-01), Segal et al.
patent: 4714681 (1987-12-01), Reading
patent: 4925648 (1990-05-01), Hansen et al.
patent: 5112946 (1992-05-01), Maione
patent: 5122464 (1992-06-01), Wilson et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5359046 (1994-10-01), Capon et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5441050 (1995-08-01), Thurston et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5573920 (1996-11-01), Randle
patent: 5585089 (1996-12-01), Queen et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5622929 (1997-04-01), Willner et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5855886 (1999-01-01), Randle
patent: 6005079 (1999-12-01), Casterman et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6130231 (2000-10-01), Wityak et al.
patent: 6277375 (2001-08-01), Ward
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6333187 (2001-12-01), Beekwilder et al.
patent: 6458933 (2002-10-01), Hansen
patent: 2003/0092042 (2003-05-01), Mu et al.
patent: 0 367 166 (1990-05-01), None
patent: 0 394 827 (1990-10-01), None
patent: 0 413 622 (1991-02-01), None
patent: 0 307 434 (1993-09-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 91/06570 (1991-05-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 92/08802 (1992-05-01), None
patent: WO 93/15199 (1993-08-01), None
patent: WO 93/15200 (1993-08-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 96/20698 (1996-07-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 99/15154 (1999-04-01), None
patent: WO 99/66903 (1999-12-01), None
patent: WO 01/77137 (2001-10-01), None
patent: WO 02/070007 (2002-09-01), None
patent: WO 03/018770 (2003-03-01), None
ATCC search output for search of murine antibodies 5B4, 1G12, 2F8, 1D7, 4B3, 2H9, 1A1, 2E11, 1D7D1 and 5B4C1 (pp. 19).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Lundkvist et al. Neuroscience Letters 200:121-124 (1995).
Floren et al. Neuropeptides 34:331-337 (2000).
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979-1983).
Ahmedin, Jemal, et al., “Recent Trends in Lung Cancer Mortality in the United States,”J. Natl. Cancer Inst., vol. 93, No. 4, pp. 277-283, Feb. 21, 2001.
Al-Lazikani, Bissan, et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,”J. Mol. Biol., vol. 273, pp. 927-948, (1997).
Altschul, Stephen F., et al. “Basic Local Alignment Search Tool,”J. Mol.Biol., vol. 215, pp. 403-410, (1990).
Ashkenazi, Avi, et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,”Proc. Natl. Acad. Sci. USA, vol. 88, pp. 10535-10539, Dec. 1991.
Bauer, F.E., et al., “Distribution and Molecular Heterogeneity of Galanin in Human, Pig, Guinea Pig, and Rat Gastrointestinal Tracts,”Gastroenterology, vol. 91, pp. 877-883 (1986).
Berger, Mitchell, et al., “Therapeutic Applications of Monoclonal Antibodies,”Am. J. Med. Sci., vol. 324, No. 1, pp. 14-30, Jul. 2002.
Bersani, Maurizio, et al., “Human Galanin: Primary Structure and Identification of Two Molecular Forms,”FEBS Letters, vol. 283, No. 2, pp. 189-194, Jun. 1991.
Boesen, Jan J.B., et al., “Circumvention of Chemotherapuy-induced Myelosuppression by Transfer of themdr1Gene,”Biotherapy, vol. 6, pp. 291-302, 1994.
Boulianne, Gabrielle L., et al., “Production of Functional Chimaeric Mouse/Human Antibody,”Nature, vol. 312, pp. 643-646, Dec. 13, 1984.
Cao, Yihai, et all, “Kringle Domains of Human Angiostatin: Characterization of the Anti-Proliferative Activity on Endothelial Cells,”J. Biol. Chem., vol. 271, No. 46, pp. 29461-29467, 1996.
Chothia, Cyrus, and Lesk, Arthur M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol., vol. 196, pp. 901-917, (1987).
Chothia, Cyrus, et al., “Conformations of Immunoglobulin Hypervariable Regions,”Nature, vol. 342, pp. 877-883, Dec. 1989.
Chothia, Cyrus, et al., “Domain Association in Immunoglobulin Molecules: The Packing of Variable Domains,”J. Mol. Biol., vol. 186, pp. 651-663 (1985).
Crowley, Craig W., et al., “Prevention of Metastasis by Inhibition of the Urokinase Receptor,”Proc. Natl. Acad. Sci. USA, vol. 90, pp. 5021-5025, Jun. 1993.
Cunningham, Brian C., and Wells, James A., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science, vol. 244, pp. 1081-1085, Jun. 2, 1989.
del Mar Lorenzo, Maria and Blasco, Rafael, “PCR-Based Method for the Introduction of Mutations in Genes Cloned and Expressed in Vaccinia Virus,”BioTechniques, vol. 24, No. 2, pp. 308-313, (1998).
DeNardo, Gerald L., et al., “Comparison of 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA)-Peptide-ChL6, a Novel Immunoconjugate with Catabolizable Linker, to 2-Iminothiolane-2-[p-(Bromoacetamido)benzyl]-DOTA-ChL6 in Breast Cancer Xenografts1,”Clin. Cancer Res., vol. 4, pp. 2483-2490, Oct. 1998.
Depczynski, B., et al., “Distribution and Characterization of the Cell Types Expressing GALR2 mRNA in Brain and Pituitary Gland,”Annals of the New York Academy of Sciences, vol. 863, pp. 120-128, (1998).
Dillman, Robert O., “Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent Developments,”Cancer Investigation, vol. 19, No. 8, pp. 833-841, (2001).
Fodde, Riccardo and Smits, Ron, “Disease Model: Familial Adenomatous Polyposis,”Trends in Molecular Medicine, vol. 7, No. 8, pp. 369-373, Aug. 2001.
Gentz, Reiner, et al., “Bioassay for Trans-activation Using Purified Human Immunodeficiency Virustat-encoded Protein: Trans-activation Requires mRNA Synthesis,”Proc. Natl. Acad. Sci. USA, vol. 86, pp. 821-824, Feb. 1989.
Goldspiel, Barry R., et al., “Human Gene Therapy,”Clinical Pharmacy, vol. 12, pp. 488-505, Jul. 1993.
Goodson, Robert J., et al., “High-Affinity Urokinase Receptor Antagonists Identified with Bacteriophage Peptide Display,”Proc. Natl. Acad. Sci. USA, vol. 91, pp. 7129-7133, Jul. 1994.
Hanahan, Douglas and Weinberg, Robert A., “The Hallmarks of Cancer,”Cell, vol. 100, pp. 57-70, Jan. 7, 2000.
Hosokawa, Yoshitaka, et al., “In vivo Analysis of Mammary and Non-Mammary Tumorigenesis in MMTV-cyclin D1 Transgenic Mice Deficient in p53,”Transgenic Research, vol. 10, pp. 471-478, (2001).
Jaffers, Gregory J., et al., “Monoclonal Antibody Therapy: Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression,”Transplantation, vol. 41, No. 5, pp. 572-578, (1986).
Jalkanen, Markku, “Cell Surface Proteoglycan of Mouse Mammary Epithelial Cells is Shed by Cleavage of its Matrix-binding Ectodomain from its Membrane-associated Domain,ȁ

Affiliated with

Also associated with

Rating

Anti-galanin antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-galanin antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-galanin antibodies and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3927715